Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03064113 | Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | PHASE2 | COMPLETED | 32 | — | — | May 1, 2011 | Oct 1, 2011 | Feb 24, 2022 | 1 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg |
| Sequence 2 | EXPERIMENTAL | Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg |
| Sequence 3 | EXPERIMENTAL | Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg |
| Sequence 4 | EXPERIMENTAL | Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | - |
| TD-4208 700 μg | DRUG | - |
| TD-4208 350 μg | DRUG | - |
| Ipratropium 500 μg | DRUG | - |
Inclusion Criteria: * Diagnosis of moderate stable Chronic Obstructive Pulmonary. * Disease with FEV1/FVC \<0.7 at screening. * Woman of non-childbearing potential. * Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth ...